BioMarin Pharmaceutical Inc. (BMRN): Price and Financial Metrics
BioMarin Pharmaceutical Inc. (BMRN)
Today's Latest Price: $77.04 USD
Updated Nov 23 4:00pm
Add BMRN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
BMRN Stock Summary
- BMRN has a market capitalization of $13,787,178,209 -- more than approximately 86.76% of US stocks.
- The price/operating cash flow metric for Biomarin Pharmaceutical Inc is higher than 95.51% of stocks in our set with a positive cash flow.
- With a year-over-year growth in debt of 71.7%, Biomarin Pharmaceutical Inc's debt growth rate surpasses 85.67% of about US stocks.
- If you're looking for stocks that are quantitatively similar to Biomarin Pharmaceutical Inc, a group of peers worth examining would be CORT, TER, RDFN, STMP, and MOMO.
- BMRN's SEC filings can be seen here. And to visit Biomarin Pharmaceutical Inc's official web site, go to www.biomarin.com.
BMRN Stock Price Chart Interactive Chart >
BMRN Price/Volume Stats
| Current price | $77.04 | 52-week high | $131.95 |
| Prev. close | $75.95 | 52-week low | $68.25 |
| Day low | $76.27 | Volume | 1,027,771 |
| Day high | $77.40 | Avg. volume | 1,782,020 |
| 50-day MA | $76.81 | Dividend yield | N/A |
| 200-day MA | $93.26 | Market Cap | 13.99B |
BioMarin Pharmaceutical Inc. (BMRN) Company Bio
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company was founded in 1996 and is based in San Rafael, California.
BMRN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $77.04 | $21890.36 | 28722% |
We started the process of determining a valid price forecast for Biomarin Pharmaceutical Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Biomarin Pharmaceutical Inc ranked in the 99th percentile in terms of potential gain offered. As the table below shows, the model suggests the stock is dramatically undervalued -- investors should note, though, that such returns are always unlikely and not to be expected. As for the metrics that stood out in our discounted cash flow analysis of Biomarin Pharmaceutical Inc, consider:
- Its compound free cash flow growth rate, as measured over the past 0.25 years, is 4.87% -- higher than 97.54% of stocks in our DCF forecasting set.
- The business' balance sheet suggests that 9% of the company's capital is sourced from debt; this is greater than merely 22.28% of the free cash flow producing stocks we're observing.
- As a business, Biomarin Pharmaceutical Inc experienced a tax rate of about 102% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 93.88% of stocks generating free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 28157% |
| 1% | 28440% |
| 2% | 28722% |
| 3% | 29005% |
| 4% | 29287% |
| 5% | 29570% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as BMRN, try KMDA, NVAX, THC, VRTX, and GEN.
Loading social stream, please wait...